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Abstract.
Background: CAIDE Dementia Risk Score is the first validated tool for estimating dementia risk based on a midlife risk
profile.
Objectives: This observational study investigated longitudinal associations of CAIDE Dementia Risk Score with brain MRI,
amyloid burden evaluated with PIB-PET, and detailed cognition measures.
Methods: FINGER participants were at-risk elderly without dementia. CAIDE Risk Score was calculated using data from
previous national surveys (mean age 52.4 years). In connection to baseline FINGER visit (on average 17.6 years later, mean
age 70.1 years), 132 participants underwent MRI scans, and 48 underwent PIB-PET scans. All 1,260 participants were
cognitively assessed (Neuropsychological Test Battery, NTB). Neuroimaging assessments included brain cortical thickness
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and volumes (Freesurfer 5.0.3), visually rated medial temporal atrophy (MTA), white matter lesions (WML), and amyloid
accumulation.
Results: Higher CAIDE Dementia Risk Score was related to more pronounced deep WML (OR 1.22, 95%CI 1.05–1.43),
lower total gray matter (-coefficient –0.29, p = 0.001) and hippocampal volume (-coefficient –0.28, p = 0.003), lower
cortical thickness (-coefficient –0.19, p = 0.042), and poorer cognition (-coefficients –0.31 for total NTB score, –0.25 for
executive functioning, –0.33 for processing speed, and –0.20 for memory, all p < 0.001). Higher CAIDE Dementia Risk Score
including APOE genotype was additionally related to more pronounced MTA (OR 1.15, 95%CI 1.00–1.30). No associations
were found with periventricular WML or amyloid accumulation.
Conclusions: The CAIDE Dementia Risk Score was related to indicators of cerebrovascular changes and neurodegeneration
on MRI, and cognition. The lack of association with brain amyloid accumulation needs to be verified in studies with larger
sample sizes.
Keywords: Aging, cognition, dementia, neuroimaging
INTRODUCTION
About one third of Alzheimer’s disease (AD)
dementia cases worldwide were estimated to be
attributable to modifiable vascular and lifestyle-
related risk factors [1]. Estimating dementia risk is
important for identifying individuals who may ben-
efit most from preventive interventions, and several
dementia risk scores have been developed [2]. How-
ever, longitudinal associations of such risk scores
with dementia-related brain changes and perfor-
mance in different cognitive domains are not fully
clear. As dementia risk scores are meant to be prac-
tical tools for prevention-related decision-making
(e.g., selecting participants in prevention trials, and
targeting the right preventive interventions toward the
right at-risk groups), it is important to investigate the
full range of properties that such tools have, includ-
ing how the estimated risk level relates to specific
brain changes and performance in different cogni-
tive domains. This knowledge can facilitate choosing
an appropriate risk score from all available options.
The crucial importance of adequate selection tools,
and of targeting interventions to at-risk groups was
recently emphasized by three large prevention trials
showing benefits of multidomain vascular/lifestyle
interventions in at-risk individuals, but not unselected
populations [3–5].
The Cardiovascular Risk Factors, Aging and
Dementia (CAIDE) Dementia Risk Score was the first
tool proposed for estimating dementia risk based on a
midlife risk profile [6], and it was validated in a large,
diverse population from the US [7]. The CAIDE
Dementia Risk Score includes age, sex, education,
blood pressure, cholesterol, body mass index (BMI),
and physical inactivity, with higher scores indicat-
ing increased risk of subsequent dementia. Another
version of the risk score additionally includes APOE
genotype [6].
Two previous studies have investigated whether
the dementia prediction ability of the CAIDE Risk
Score was related to different types of brain changes.
A longitudinal population-based study reported that
a higher CAIDE score was associated with more
severe visually rated white matter lesions (WML) and
medial temporal lobe atrophy (MTA) on magnetic
resonance imaging (MRI) [8]. In a cross-sectional
study of memory clinic patients without dementia, a
higher CAIDE score was associated with more severe
WML and MTA on MRI, as well as AD-related cere-
brospinal fluid (CSF) biomarkers: higher total tau,
and lower amyloid- (A)/tau ratio [9]. However, it
is not clear whether these findings would also apply
to a general population.
The relations of the CAIDE Risk Score with cogni-
tion were previously investigated in two longitudinal
population-based studies with different cognitive
assessments. One study focused on cognitive decline
based on five tests, and reported associations of higher
CAIDE score with more decline in global cogni-
tion, reasoning, and vocabulary, but not memory or
fluency domains [10]. Another study with a more
detailed test battery focused on cognitive impairment
defined as performance below a specified cut-off, and
reported associations of higher CAIDE score with
impairment in processing speed, visuoconstruction,
and reasoning, but not executive functioning, lan-
guage, or memory [11].
The aims of this longitudinal study in older
individuals without dementia from the general pop-
ulation are to investigate associations of CAIDE
Dementia Risk Score with: 1) more detailed
neuroimaging assessments, including Pittsburgh
Compound B (PIB)-positron emission tomography
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(PET) measures of brain A deposition, and MRI
measures of hippocampus and total gray matter (GM)
volume, cortical thickness, visually rated deep and
periventricular WML, and MTA; and 2) performance
in several cognitive domains assessed with a compre-
hensive test battery previously used in AD clinical
trials.
MATERIALS AND METHODS
Study population
This study included participants in the Finnish
Geriatric Intervention Study to Prevent Cog-
nitive Impairment and Disability (FINGER,
NCT01041989) with MRI scans (n = 132), PIB-
PET scans (n = 48), and cognitive tests (n = 1260)
conducted in connection to the baseline FINGER
visit. FINGER participants [3, 12, 13] were selected
from previous population-based non-intervention
cohort studies: the National FINRISK Study [14]
and FIN-D2D [15, 16]. The present study focused on
the CAIDE Dementia Risk Score calculated based
on FINRISK and FIN-D2D data, and neuroimaging
and cognition data collected in connection to the
baseline FINGER visit (Fig. 1). Mean age (standard
deviation, SD) for the 1,260 FINGER participants
was 56.2 (10.7) years at the FINRISK or FIN-D2D
visit, and 69.4 (4.7) years at the FINGER baseline
visit, and mean (SD) time between the FINRISK or
FIN-D2D visit and baseline FINGER visit was 13.1
(9.9) years, range 2–39 years.
The FINRISK, FIN-D2D, and FINGER studies
have been previously described in detail ([3, 12–16]
and Supplementary Material). In 2009–2011, 1,260
participants in either FINRISK or FIN-D2D non-
intervention surveys were selected to participate in
the FINGER study. To be eligible, they had to be
60 to 77 years old, with the CAIDE Dementia Risk
Score ≥6 points, and cognitive performance at the
mean level or slightly lower than expected for age
according to Finnish population norms for Consor-
tium to Establish a Registry for Alzheimer’s Disease
(CERAD) neuropsychological battery [17]. People
with dementia and substantial cognitive impairment
were excluded.
Ethical approval for the FINRISK surveys was
obtained according to commonly required proce-
dures since 1972 from local Ethics Committees that
have varied over time (Coordinating Ethics Commit-
tee for the Uusimaa Hospital District since 2007).
From 1997 onwards, written informed consent was
obtained from each participant. The FINGER study
was approved by the Coordinating Ethics Committee
of the Hospital District of Helsinki and Uusimaa, and
all participants gave written informed consent.
Measurements of CAIDE Dementia Risk Score
factors in FINRISK and FIN-D2D surveys
The methodology of the FINRISK study surveys
has been kept as similar as possible over the years
and has been previously described in detail ([14]
and Supplementary Material). The 1972 and 1977
surveys were largely comparable to later surveys
1982-92 where methodology closely followed the
WHO MONICA protocol [18] and the later recom-
mendations of the European Health Risk Monitoring
project [19]. FIN-D2D survey methodology was
based on FINRISK surveys ([15, 16] and Supplemen-
tary Material).
The surveys included a self-administered question-
naire, physical measurements, and blood samples.
The CAIDE Dementia Risk Score for each sub-
ject was calculated based on FINRISK or FIN-D2D
data (age, sex, years of formal education, systolic
blood pressure, BMI, serum total cholesterol, and
physical activity) according to previously specified
cut-offs and number of points [6] (Supplementary
Table 1). In addition, as specified in the original pub-
lication [6], a CAIDE Dementia Risk Score including
apolipoprotein E (APOE) genotype was also calcu-
lated. For APOE assessment in FINGER, genomic
DNA was extracted from venous blood samples
with Chemagic MSM1 from PerkinElmer using mag-
netic beads. APOE genotyping was determined by
polymerase chain reaction using TaqMan genotyp-
ing assays (Applied Biosystems (ABI), Foster City,
CA, USA) for two single-nucleotide polymorphisms
(rs429358 and rs7412) and an allelic discrimination
method on the ABI 7500 platform [20].
Cognitive assessments in the FINGER study
An extended version of the neuropsychological test
battery (NTB) [21] was used for cognitive assess-
ments in the FINGER study. The NTB total score
was calculated as a composite score based on results
from 14 tests (Z scores standardized to the baseline
mean and SD; for higher scores to indicate better per-
formance, scores were inversed if needed, e.g., trail
making test) [12]. An executive functioning score
was similarly calculated from Z scores for category
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Fig. 1. Overview of the study design.
fluency test [17], digit span, concept shifting test
(condition C), trail making test (shifting score B–A),
and a shortened 40-stimulus version of the original
Stroop test (interference score 3–2). A processing
speed score was calculated from Z scores for letter
digit substitution test, concept shifting test (condi-
tion A), and Stroop test (condition 2). A memory
score was calculated using Z scores for visual paired
associates test immediate and delayed recall, logical
memory immediate and delayed recall, and word list
learning and delayed recall [3]. The minimum num-
ber of necessary NTB components was set to eight
of 14 for calculating NTB total score, three of five
for executive functioning, two of three for processing
speed, and three of six for memory [3]. An abbrevi-
ated memory score included four of six tests (two
associative memory and two logical memory tests)
with longer recall delay (30 min instead of 5 min) and
requiring more complex processing. Mini-Mental
State Examination [22] was also administered.
MRI assessments in the FINGER study
Brain MRI scans were conducted for a subsam-
ple of 155 FINGER participants from four of the
six study sites. Participants were selected from the
most recently recruited individuals at the time when
MRI/PET resources became available at a specific
site, and if there were no contraindications. 132 scans
from three study sites passed quality control (all
18 scans from one site excluded due to acquisition
issues, and 5 additional scans excluded due to old
brain infarcts which may have affected automated
image analysis). Data acquisition was conducted
using four different MR systems (one General Elec-
tric 1.5T, two Siemens 1.5T, and one Philips Gemini
PET/MRI 3T). Images were quality checked and read
for any abnormalities, and regional cortical thick-
ness and volumes were measured using the Freesurfer
image analysis suite (version 5.0.3). Total GM vol-
ume and hippocampus volume were normalized to
total intracranial volume to correct for head size. A
measure of cortical thickness in AD signature regions
was calculated as the average of cortical thickness in
entorhinal, inferior temporal, middle temporal, and
fusiform regions as previously described [23].
A single rater blinded to clinical data assessed
MTA from T1-weighted images according to a visual
rating scale commonly used in clinical practice
[24]. MRIs were oriented perpendicular to the ante-
rior commisure-posterior commisure line and MTA
was rated from single coronal slice at the level
where hippocampus, cerebral peduncles, and pons
were all visible. MTA was graded from 0 (no atro-
phy) to 4 (end-stage atrophy) bilaterally [24]. WML
were assessed from FLAIR images using a semi-
quantitative visual rating scale [25] by a single rater
blinded to clinical data. Periventricular WML were
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Table 1
Comparison between FINGER participants with and without brain scans at the three neuroimaging study sites (total 682 participants)∗∗
n No brain scan n Brain scan p
MRI POPULATION
Men, n (%) 550 292 (53.0) 132 70 (53.0) 0.99
Education, years 546 9.5 (3.07) 132 9.4 (2.9) 0.75
APOE ε4 carriers, n (%) 507 175 (34.5) 119 35 (29.4) 0.28
# Follow-up time, years 550 16.0 (11.0) 132 17.6 (9.3) 0.13
Characteristics at the FINRISK/FIN-D2D assessment
Age, years 550 53.0 (11.4) 132 52.4 (10.6) 0.56
Systolic blood pressure, mmHg 548 141.0 (18.4) 132 141.2 (20.7) 0.95
BMI, kg/m2 548 27.4 (4.3) 132 26.9 (3.4) 0.20
Total cholesterol, mmol/l 547 5.9 (1.1) 132 5.9 (1.1) 0.78
Physically inactive, n (%) 542 255 (47.0) 131 70 (53.4) 0.18
CAIDE Dementia Risk Score 535 7.13 (2.5) 131 6.8 (2.4) 0.18
CAIDE Dementia Risk Score including APOE 492 8.7 (3.10) 118 8.2 (2.8) 0.14
Characteristics at the FINGER baseline assessment
Age, years 550 69.2 (4.7) 132 70.1 (4.6) 0.06
NTB Total score 549 –0.12 (0.56) 132 –0.067 (0.52) 0.25
NTB Executive functioning 548 –0.14 (0.67) 132 –0.04 (0.58) 0.10
NTB Processing speed 549 –0.13 (0.82) 132 –0.04 (0.78) 0.23
NTB Memory 549 –0.10 (0.64) 132 –0.10 (0.60) 0.90
NTB Abbreviated memory 539 –0.15 (0.7) 132 –0.14 (0.70) 0.94
MMSE 549 26.9 (1.98) 130 26.9 (1.99) 0.63
∗Visually rated deep WML – – 131 1.2 (0.0–3.0) –
∗Visually rated periventricular WML – – 131 1.4 (0.0–3.0) –
∗Visually rated MTA – – 132 1.0 (0.0–3.0) –
∗Total hippocampal volume, ml – – 132 7.3 (4.7–9.3) –
∗Total intracranial volume, ml – – 132 1559.6 (957.9–2032.7) –
∗AD signature thickness, mm – – 132 2.8 (2.4–3.1) –
∗Total GM volume, ml – – 132 554.6 (420.7–695.4) –
PET POPULATION
Men, n (%) 191 98 (51.3) 48 26 (54.17) 0.72
Education, years 189 9.4 (3.30) 48 9.40 (3.09) 0.97
APOE ε4 carriers, n (%) 180 76 (42.2) 47 14 (29.7) 0.12
# Follow-up time, years 191 11.1 (7.13) 48 21.3 (3.0) <0.001
Characteristics at baseline (FINRISK/FIN-D2D assessment)
Age, years 191 58.9 (7.7) 48 49.1 (5.9) <0.001
Systolic blood pressure, mmHg 190 141.0 (19.4) 48 136.20 (22.2) 0.13
BMI, kg/m2 190 27.9 (4.14) 48 26.6 (3.0) 0.05
Total cholesterol, mmol/l 190 5.84 (1.1) 48 6.0 (1.1) 0.38
Physically inactive, n (%) 190 82 (43.1) 48 31 (64.5) 0.008
CAIDE Dementia Risk Score 187 7.90 (1.90) 48 6.52 (3.0) <0.001
CAIDE Dementia Risk Score including APOE 176 9.8 (2.42) 47 7.83 (3.14) <0.001
Characteristics at the FNGER baseline assessment
Age, years 191 70.0 (4.6) 48 70.7 (5.04) 0.35
NTB Total score 190 –0.05 (0.52) 48 –0.01 (0.52) 0.67
NTB Executive functioning 190 –0.10 (0.64) 48 –0.0001 (0.56) 0.30
NTB Processing speed 190 –0.10 (0.76) 48 0.05 (0.89) 0.23
NTB Memory 190 0.02 (0.59) 48 –0.048 (0.58) 0.44
NTB Abbreviated memory 184 –0.020 (0.69) 48 –0.13 (0.67) 0.33
MMSE 191 27.2 (2.02) 48 27.0 (1.8) 0.52
Amyloid positive, n (%) – – 48 20 (41.6) –
Values are means (SD) unless otherwise specified. ∗Values are medians (range). P-values are shown for differences between participants with
and without brain scans. # Follow-up time is calculated as time between FINRISK/FIN-D2D visit and FINGER baseline visit. ∗∗Due to the
geographical distribution of the different FINRISK/FIN-D2D cohorts, recruitment was primarily from earlier cohorts at neuroimaging study
sites (i.e., younger participants), and primarily from later cohorts at study sites without neuroimaging (i.e., older participants). The comparisons
shown in the table focused on the neuroimaging sites in order to assess if there were further differences between groups. APOE, apolipoprotein
E genotype; BMI, body mass index; CAIDE, Cardiovascular Risk Factors, Aging and Dementia study; NTB, neuropsychological test battery;
MMSE, Mini-Mental State Examination; WML, white matter lesions; MTA, medial temporal atrophy; AD signature thickness, Alzheimer’s
disease signature thickness, average of cortical thickness in entorhinal, inferior temporal, middle temporal, and fusiform regions; GM,
gray matter.
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rated as 0 (absence), 1 (caps or pencil-thin lining), 2
(smooth halo), and 3 (irregular WML extending into
the deep WM). Deep WML were rated as 0 (absence),
1 (punctate foci), 2 (beginning confluence of foci),
and 3 (large confluent areas).
PET assessments in the FINGER study
PIB-PET was performed in one center (Turku Uni-
versity Hospital). [11C] PIB (N-methyl-[11 C]2-(4
methylaminophenyl)-6-hydroxybenzothiazole) was
produced as described earlier [26]. On average
406.3 (SD 107.7) MBq of PIB was injected intra-
venously and a scan from 60–90 min (3 × 10 min
frames) after injection was performed with a Philips
Ingenuity TF PET/MR scanner (Philips, Amster-
dam, the Netherlands). The scans were visually
interpreted by two experienced readers and judged
as visually positive or negative after consensus
agreement.
Statistical analysis
Statistical analyses were done using Stata software
version 12. The level of statistical significance was
p < 0.05 in all analyses. Comparisons between FIN-
GER participants with and without MRI or PET data
were made using t-test or chi-square test as appro-
priate. Ordinal logistic regression was used to assess
associations between CAIDE Dementia Risk Score,
CAIDE Dementia Risk Score including APOE, and
the following MRI measures (some additional cat-
egorizations were done to avoid too small groups):
visually rated deep WML (3 groups with ratings
0, 1, and 2-3); visually rated periventricular WML
(4 groups with ratings from 0 to 3); and visually
rated MTA (the mean of left and right MTA rat-
ings, 3 groups with ratings 0–0.5, 1, and 1.5–3).
Brant command [27] was used to test proportional
odds assumption. Binary logistic regression was used
to assess associations between CAIDE Dementia
Risk Score versions and amyloid positivity on PIB-
PET scans (negative, n = 28 versus positive, n = 20
subjects). After zero-skewness log-transformation,
linear regression was used to assess associations with
total intracranial volume-normalized total GM and
hippocampal volume, and AD signature thickness
(average of cortical thickness in entorhinal, inferior
temporal, middle temporal, and fusiform regions)
[23]. All analyses were adjusted for site (except for
amyloid positivity because PIB-PET scans were con-
ducted in one site) and follow-up time. Results are
reported as odds ratios (OR) and 95% confidence
intervals (CI).
Linear regression models with cognitive test scores
as dependent variables were used to analyze associa-
tions between CAIDE Dementia Risk Score, CAIDE
Dementia Risk Score including APOE, and cognition
(adjusted for time between the FINRISK or FIN-D2D
visit and FINGER baseline visit). Results are shown
as standardized -coefficients and p-values.
RESULTS
The recruitment to the FINGER study from the
FINRISK and FIN-D2D surveys has been previously
described in detail [13], and summarized in Supple-
mentary Table 2. Table 1 shows characteristics of
FINGER participants with and without neuroimag-
ing data at the three study sites where brain scans
were available (total 682 participants, of which 132
had MRI and 48 had PIB-PET scans). The MRI
population was not significantly different from the
population without MRI at these sites (Table 1). The
PET population was significantly younger at the FIN-
RISK Study visit, had longer follow-up time, was
more often physically inactive, and had lower CAIDE
Dementia Risk Score at the FINRISK visit compared
with participants without PET data. Cognition and
other characteristics were not significantly different
between participants with and without neuroimaging
data.
Due to the geographical distribution of the dif-
ferent FINRISK/FIN-D2D cohorts, recruitment was
primarily from earlier cohorts at neuroimaging study
sites, and primarily from later cohorts at study sites
without neuroimaging (Supplementary Table 2). This
resulted in a significant difference in age at the
FINRISK/FIN-D2D visit (p < 0.001). Mean age (SD)
was 52.9 (11.3) years for the 682 participants from
neuroimaging sites, and 60.1 (8.5) years for the 578
participants from study sites without neuroimaging.
Associations of the CAIDE Dementia Risk Score,
and CAIDE Dementia Risk Score including APOE
with MRI and PIB-PET measures are shown in
Table 2. Higher CAIDE Dementia Risk Score was
significantly related to more pronounced deep WML
(p = 0.010), lower hippocampal volume (p = 0.003),
lower total GM volume (p = 0.001), and lower
AD signature cortical thickness (p = 0.042). Higher
CAIDE Dementia Risk Score including APOE was
significantly related to more pronounced deep WML
(p = 0.006), more pronounced MTA (p = 0.038),
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Table 2
Associations of CAIDE Dementia Risk Score with neuroimaging biomarkers
CAIDE Dementia CAIDE Dementia Risk Score
Risk Score including APOE
n OR (95% CI) n OR (95% CI)
More pronounced deep WML 130 1.22 (1.05–1.43) 117 1.22 (1.06–1.40)
More pronounced periventricular WML 130 1.09 (0.97–1.25) 117 1.05 (0.93–1.18)
More pronounced MTA 131 1.09 (0.95–1.27) 118 1.15 (1.00–1.30)
Amyloid positivity on PIB-PET 48 1.03 (0.84–1.25) 47 1.13 (0.93–1.38)
Standardized -coefﬁcient (p-value)
Hippocampal volume 131 –0.28 (0.003) 118 –0.33 (0.001)
AD signature thickness 131 –0.19 (0.042) 118 –0.24 (0.02)
Total GM volume 131 –0.29 (0.001) 118 –0.26 (0.009)
OR and 95% CI from ordinal or binary logistic regressions with neuroimaging measures as outcomes:
• Visually rated deep WML (3 groups by Fazekas scale of severity: 0 for n = 17 subjects; 1 for n = 71; and 2-3 for n = 43).
• Visually rated periventricular WML (4 groups by Fazekas scale of severity: 0 for n = 25 subjects; 1 for n = 45; 2 for n = 36; and 3 for
n = 25).
• Visually rated MTA (3 groups by Scheltens scale of severity: 0–0.5 for n = 20 subjects, 1 for n = 67, and 1.5–3 for n = 45).
• Amyloid accumulation on PIB-PET (negative n = 28 subjects, positive n = 20 subjects).
Standardized -coefficients (p-values) from linear regressions with hippocampal and GM volume, and cortical thickness as outcomes.
All analyses are adjusted for follow-up time and study site (except PIB-PET – scans conducted in one site). APOE, apolipoprotein E
genotype; CAIDE, Cardiovascular Risk Factors, Aging and Dementia study; WML, white matter lesions; MTA, medial temporal atrophy;
AD signature thickness, Alzheimer’s disease signature thickness, average of cortical thickness in entorhinal, inferior temporal, middle
temporal, and fusiform regions; GM, gray matter.
lower hippocampal volume (p = 0.001), lower total
GM volume (p = 0.009), and lower AD signature
cortical thickness (p = 0.018). No significant asso-
ciations were found with periventricular WML or
amyloid positivity on PIB-PET scans.
A higher CAIDE Dementia Risk Score at the FIN-
RISK/D2D visit was significantly associated with
poorer cognitive performance in all domains at the
baseline FINGER visit (Table 3). The same was found
for CAIDE Dementia Risk Score including APOE.
DISCUSSION
The present study showed that a higher baseline
CAIDE Dementia Risk Score was significantly asso-
ciated with more pronounced deep WML, lower total
GM and hippocampal volume, and lower cortical
thickness in AD signature areas at follow-up. Higher
CAIDE Dementia Risk Score including APOE was
additionally related to more pronounced MTA. There
were no significant relations with periventricular
WML or amyloid accumulation on PIB-PET scans.
A higher CAIDE Dementia Risk Score was signifi-
cantly related to poorer cognition, and the same was
found for CAIDE Dementia Risk Score including
APOE.
The CAIDE Dementia Risk Score based on a
midlife risk profile is known to perform well in
predicting dementia 20 to 40 years later [6, 7], and has
also been associated with cognitive impairment [11]
or cognitive decline [10] in several domains, but not
memory or executive functioning. In the present study
of individuals without dementia, the CAIDE Demen-
tia Risk Score was related to subsequent cognitive
performance across multiple domains, including
memory and executive functioning. Differences in
findings compared to previous studies may be due
to the use of different cognitive tests. The present
study included a very comprehensive test battery
that was previously used in AD clinical trials [21],
and all cognitive domains were defined as compos-
ite scores based on several tests, which are likely
to be more sensitive measures compared to a single
test. Another explanation may be population differ-
ences. Previous studies have focused on unselected
general populations without dementia from the UK
and the Netherlands [10, 11]. FINGER participants
represented a general Finnish population at risk for
dementia, but without dementia or pronounced cog-
nitive impairment (mean cognitive performance was
less than 0.5 SD below the average level of a cogni-
tively normal Finnish population) [13].
The CAIDE Dementia Risk Score is based pri-
marily on vascular factors, and a higher score in
midlife was previously shown to relate to more severe
WML 20 to 30 years later [8]. The associations with
deep WML but not periventricular WML observed
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Table 3
Longitudinal associations between CAIDE Dementia Risk Score and cognitive functioning at the FINGER baseline visit
n CAIDE Dementia Risk n CAIDE Dementia Risk
Score Score including APOE
NTB total score 1,144 = –0.31 (p < 0.001) 1,061 = –0.41 (p < 0.001)
NTB Executive functioning 1,143 = –0.25 (p < 0.001) 1,060 = –0.35 (p < 0.001)
NTB Processing speed 1,144 = –0.33 (p < 0.001) 1,061 = –0.37 (p < 0.001)
NTB Memory 1,144 = –0.20 (p < 0.001) 1,061 = –0.29 (p < 0.001)
NTB Abbreviated memory 1,126 = –0.20 (p < 0.001) 1,044 = –0.29 (p < 0.001)
MMSE 1,142 = –0.12 (p = 0.001) 1,059 = –0.16 (p < 0.001)
Values are standardized beta-coefficients (p-values) from linear regressions with cognitive tests as dependent variables.
APOE, apolipoprotein E genotype; CAIDE, Cardiovascular Risk Factors, Aging and Dementia study; NTB, Neuropsycho-
logical Test Battery; MMSE, Mini-Mental State Examination.
in the present study further support the link between
the CAIDE Dementia Risk Score and cerebrovascu-
lar changes on brain MRI. Deep and periventricular
WML are considered to be the result of different
pathological processes, i.e., deep WML are regarded
as markers for cerebral small vessel disease, related
disturbances in white matter perfusion and ischemia,
while periventricular WML may be the result of, e.g.,
blood-brain barrier dysfunction or disturbances in
CSF production [28].
A higher CAIDE Dementia Risk Score has been
associated with more pronounced MTA 30 years later
in a population-based study [8], and also in a cross-
sectional study of memory clinic patients without
dementia [9]. In the present study, higher CAIDE
Dementia Risk Score was additionally associated
with lower total GM and hippocampal volume, and
lower cortical thickness in AD signature brain areas.
However, no associations were found with amyloid
positivity on PIB-PET scans. This is in contrast to the
cross-sectional study of memory clinic patients with-
out dementia, where a higher CAIDE Dementia Risk
Score (version with APOE) was related to lower CSF
A1–42 [9]. Several factors may at least partly explain
the conflicting results: compared with FINGER par-
ticipants, memory clinic patients without dementia
are highly selected, most likely located further down-
stream in the temporal evolution of AD biomarkers;
cross-sectional versus longitudinal design; and small
PIB-PET sample size in the present study. In addition,
disagreements between CSF and PET findings have
been previously reported in individuals without pro-
nounced cognitive symptoms, e.g., amyloid positive
CSF with amyloid negative PET [29].
Brain amyloid accumulation does not have a
straightforward relation to dementia or cognitive
impairment [30, 31]. In the present study, 41.6%
of participants were amyloid-positive on PIB-PET
despite exclusion of dementia or substantial cognitive
impairment. The significance of a positive PIB-PET
scan in asymptomatic individuals is not fully clear.
The new research criteria for AD have mentioned
two different situations: preclinical AD (i.e., the dis-
ease is already present as shown by co-occurrence of
both amyloidopathy and tauopathy), and an asymp-
tomatic at-risk state (i.e., increased risk for future AD
development as shown by isolated amyloidopathy or
tauopathy) [32]. The natural history of these two
states, especially concerning potential progression
to dementia, still needs clarifications. Considering
the increasing interest in dementia prevention tri-
als targeting preclinical AD and/or asymptomatic
at-risk states [33], investigating potential predictors
of amyloid positivity in asymptomatic individuals is
important for, e.g., determining which risk estimation
tools may be useful for reducing screening failures in
these types of trials.
Our findings suggest the possibility that the per-
formance of the CAIDE risk score in predicting
dementia in the general population may not be
directly related to prediction of amyloid pathology.
Medial temporal atrophy and atrophy in other brain
regions can occur through mechanisms unrelated to
amyloid accumulation or AD [23, 34–37]. Midlife
vascular and lifestyle-related risk factors included
in the CAIDE Dementia Risk Score (e.g., hyper-
tension, obesity, hypercholesterolemia, or physical
inactivity) have previously been associated with brain
atrophy [37], but their associations with brain amy-
loid pathology in clinical-pathological studies have
been inconsistent [38]. Cerebrovascular and amyloid
pathologies are often present simultaneously, espe-
cially at older ages, and they have been shown to
interact at cellular and molecular level [39]. Regard-
ing AD, it is still debated if the entire pathological
cascade is initiated by A, or if A deposition and
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neuronal injury are partly independent events [40].
The main strengths of the present study are longi-
tudinal population-based design, and availability of
detailed cognitive and neuroimaging assessments at
the follow-up exam (although not at the baseline
FINRISK/FIN-D2D surveys). MRI scanners were
different between study sites, but this was adjusted for
in the analyses. In addition, Freesurfer morphomet-
ric procedures have previously shown good test-retest
reliability across scanner manufacturers and field
strengths [41, 42].
The main limitation of the study is that FINGER
neuroimaging sample sizes were small, particularly
the PIB-PET sample (n = 48), which limited statis-
tical power and thus the possibility to identify an
association between the CAIDE risk score and brain
amyloid deposition. Selection bias may have also
reduced the ability to identify associations with neu-
roimaging measures for several reasons: 1) Overall,
the FINGER population included individuals at risk
for dementia, and does not fully reflect the entire risk
continuum (from low to high) observed in the gen-
eral population; 2) Age is a central risk factor for
dementia and related brain pathology, and partici-
pants from study sites without neuroimaging were
older at the midlife FINRISK/FIN-D2D visit; also, at
study sites with neuroimaging, participants without
PIB-PET scans were older than those with PIB-PET
scans; and 3) Exclusion of MRI scans of inadequate
quality led to the exclusion of 5 individuals with
old brain infarcts, which may have underestimated
associations of CAIDE score with cerebrovascular
changes including WML, as higher vascular risk is
related to higher risk of cerebrovascular disease. In
addition, FINGER participants did not have substan-
tial cognitive impairment, and it is not yet clear how
many of them will actually develop dementia in the
future (an extended follow-up is currently ongoing).
In conclusion, the CAIDE Dementia Risk Score
was related to indicators of cerebrovascular changes
and neurodegeneration on MRI, but not to brain
amyloid accumulation on PIB-PET. The CAIDE
Dementia Risk Score is a simple and easily available
tool for evaluating dementia risk profiles in midlife,
and it is also related to WML, markers of brain atro-
phy, and cognitive performance in late-life. The lack
of association with brain amyloid accumulation in
this at-risk general population contrasts with reported
links to AD-related CSF biomarkers in a memory
clinic setting, and will need to be confirmed in studies
with larger sample size.
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